Ticagrelor

替格瑞洛

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameTicagrelor
Drug Alias Name替卡格雷ticagrelorum替卡瑞劳替格雷洛Possia +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsCommunity Acquired PneumoniaIschemic StrokeDrug-Related Side Effects and Adverse Reactions +[33] 
Global Approved IndicationsPeripheral Vascular DiseasesMyocardial InfarctionAcute Coronary Syndrome
Approved Indications in ChinaAcute Coronary Syndrome
Original Approved Country/TerritoryEU
Original Approved Date2010/12/03
Country/TerritoryCzechiaBelgiumBulgaria +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute of Cardiovascular Diseases, PakistanBio-innova Co LtdWeill Medical College of Cornell University +[12] 
Inactive CompaniesUniversity Of KarachiUniversity Of The West IndiesAzienda Ospedaliero Universitaria Di Sassari +[14] 
Active IndicationsIschemic StrokePeripheral Vascular DiseasesThrombosis +[13] 
Inactive IndicationsCommunity Acquired PneumoniaDrug-Related Side Effects and Adverse ReactionsIschemia +[20] 

Other Information

ATC CodeB01AC24
Related LinksWikipediaDrugBankKEGG